Ozempic

On Weight Loss, Spider-Man and Cartel Collaboration

Why diet and exercise if you can just take a pill?

Or get an injection, for that matter.

Let’s start off with the injection.

Last year, and against my better judgment, I watched Spider-Man No Way Home.

Here is the final scene.

In a nutshell, at minute 5.20, the bad guy is injected by the good guy, and is restored to being a good guy. The End.

Here is a more detailed explanation of what is happening.

In the climactic finale of "Spider-Man: No Way Home," the character Green Goblin, portrayed by Willem Dafoe, is indeed cured of his malevolent alter ego. The antidote administered to him is developed by Peter Parker (played by Tom Holland) and his allies. The serum specifically targets the Green Goblin's affliction, neutralising the effects of the original Goblin serum that had transformed Norman Osborn into the supervillain.

Upon receiving the cure, the aggressive and unstable persona of the Green Goblin is suppressed, allowing Norman Osborn's true consciousness to resurface, free from the influence of the Goblin. This restoration of his sanity is accompanied by a reversal of the Goblin's physical mutations, such as his enhanced strength and deteriorated appearance.

As Osborn regains his faculties, he expresses remorse for his actions while under the Goblin's influence, showing gratitude towards Spider-Man for the redemption he's been afforded. The film concludes with Osborn's future left open-ended, without a definitive resolution to his character arc.

I understood what I was watching in real time.

Not that long ago, everybody was smoking in the movies. Big Tobacco, via movies, was socially engineering the normalization of smoking.

Today, Big Pharma, via movies, is socially engineering the normalization of injections and medical interventions, for any and all problems, including, as is the case with the Green Goblin, moral ones.

This article is mainly about Ozempic, but for me it is also about Cartel Collaboration.

The problems generated from one cartel’s profiteering is the opportunity for the next cartel’s profiteering.

My thesis is that “hunger” is both a side effect and an explicit objective of one cartel, Big Food.

Leading to obesity.

While “hunger management” is the opportunity for the next cartel, Big Pharma.

It’s so beautifully symbiotic.

Let’s start…

What is Hunger?

Hunger, the physiological need for food, is influenced by several factors:

1. Blood Sugar Levels: When blood sugar drops, the body signals hunger.

2. Ghrelin: Known as the "hunger hormone," ghrelin levels increase before meals and decrease after eating.

3. Leptin: This hormone, produced by fat cells, signals satiety and regulates energy balance.

4. Stomach Emptying: The rate at which the stomach empties can influence hunger feelings.

5. External Factors: Sight, smell, and thought of food can trigger hunger.

6. Nutritional Deficiencies: Lack of certain nutrients can cause increased hunger.

7. Psychological Factors: Stress, boredom, and other emotional states can affect hunger.

What is the impact of highly processed food on Hunger?

Highly processed foods often contribute to persistent hunger due to:

1. High Glycemic Index: These foods can cause rapid spikes and drops in blood sugar, leading to recurrent hunger.

2. Low Fiber Content: Fiber promotes fullness; processed foods typically have less fiber.

3. High Fat and Sugar Content: These ingredients can alter the balance of hunger and satiety hormones, like leptin and ghrelin.

4. Additives: Some additives may interfere with the body's hunger and fullness signals.

5. Caloric Density: Processed foods can be calorie-dense but not filling, leading to increased food intake.

6. Taste and Palatability: Enhanced flavors can override natural satiety cues, leading to overeating.

These factors combined can create a cycle of continuous hunger and overeating, particularly when consuming highly processed foods.

Which receptors are most involved in the Hunger mechanism?

The hunger mechanism in the human body is regulated by a complex network of receptors and hormones. The key receptors most involved in this mechanism are:

1. Ghrelin Receptors: Ghrelin, often called the "hunger hormone," is produced in the stomach and binds to receptors in the hypothalamus, a brain region that regulates appetite. When ghrelin levels are high, it stimulates appetite, signaling the body to eat.

2. Leptin Receptors: Leptin, produced by fat cells, binds to receptors in the hypothalamus as well. It signals satiety or fullness, reducing the urge to eat. Leptin resistance, where the body doesn't respond adequately to leptin, can lead to increased hunger and weight gain.

3. Insulin Receptors: Insulin, secreted by the pancreas, also plays a role in hunger regulation. Insulin receptors in the brain help regulate energy balance and body weight. When insulin levels rise after eating, it helps reduce hunger signals.

4. Neuropeptide Y (NPY) Receptors: NPY is a potent stimulator of feeding behavior. It is produced in the hypothalamus and binds to specific receptors, stimulating appetite and food intake.

5. Glucagon-Like Peptide-1 (GLP-1) Receptors: GLP-1, produced in the gut and brain, enhances insulin secretion and inhibits glucagon release, leading to decreased appetite and food intake.

6. Melanocortin Receptors: These receptors are involved in the regulation of energy balance and food intake. Activation of these receptors can suppress appetite.

7. Cannabinoid Receptors: Especially the CB1 receptor, plays a role in the regulation of appetite and feeding behavior. Activation of these receptors can increase appetite.

These receptors work in concert with various hormones, neurotransmitters, and other signaling molecules to regulate hunger and satiety, maintaining energy balance in the body.

How are these receptors affected by highly processed food?

Highly processed foods can significantly impact the receptors involved in hunger and satiety mechanisms, often leading to altered eating behaviors. Here's how these foods affect key receptors:

1. Ghrelin Receptors: Processed foods, especially those high in simple carbohydrates and sugars, can cause a rapid rise and fall in blood sugar levels. This fluctuation may lead to a quicker return of ghrelin levels to a state that signals hunger, prompting more frequent eating.

2. Leptin Receptors: High-fat, calorie-dense processed foods can contribute to leptin resistance. In this condition, despite having adequate or high levels of leptin, the brain doesn't adequately receive the satiety signal, leading to overeating.

3. Insulin Receptors: Processed foods high in sugars and refined carbohydrates cause sharp spikes in insulin levels. Over time, this can lead to insulin resistance, where the body's response to insulin is diminished, affecting the normal hunger-suppressing role of insulin.

4. Neuropeptide Y (NPY) Receptors: Diets high in processed foods can stimulate the production of NPY, which in turn increases appetite and food intake, especially for carbohydrates.

5. Glucagon-Like Peptide-1 (GLP-1) Receptors: Processed foods, being low in fiber, may reduce the secretion of GLP-1, diminishing its role in promoting feelings of fullness and reducing food intake.

6. Melanocortin Receptors: The consumption of high-energy, nutrient-poor processed foods can disrupt the normal functioning of these receptors, leading to increased food intake and reduced energy expenditure.

7. Cannabinoid Receptors: Certain components in processed foods may indirectly stimulate these receptors, enhancing the pleasure and reward aspects of eating, which can lead to overconsumption.

In summary, highly processed foods can disrupt the normal functioning of hunger and satiety receptors and hormones. This disruption often leads to a cycle of rapid blood sugar fluctuations, insulin resistance, leptin resistance, and increased appetite, contributing to overeating and potential weight gain.

So, Big Food manufactures Hunger.

Hunger gets you to Obesity.

Along comes Big Pharma with a solution.

The active ingredient is Semaglutide and it is sold as Ozempic, Wegovy etc.

Here is an analogy of how it works:

In simple terms, the drugs Wegovy, Ozempic, Saxenda, and Victoza contain an active ingredient called semaglutide. This ingredient belongs to a group of drugs known as GLP-1 receptor agonists. These drugs work by enhancing the effects of a hormone in your body called GLP-1.

To understand this with an analogy, imagine your stomach is like a sink with a drain. Normally, when you eat, it's like turning on the tap – the sink fills up, and then the water drains out at a regular pace. The hormone GLP-1 is like a plug that can slow down the draining of water from the sink. When you take a GLP-1 agonist drug, it's like pushing that plug in further, making the water (or food, in the case of your stomach) drain out more slowly. As a result, the sink stays full for a longer time. In the context of your stomach, this means you feel fuller for a longer period after eating, which can help reduce your overall food intake and assist in weight loss.

How much does it slow down the emptying of the stomach?

Studies investigating liraglutide, another drug in the GLP-1 agonist category, demonstrated a significant decrease in digestive speed. For individuals taking liraglutide, the average time for half of their consumed food to leave the stomach was recorded at approximately 70 minutes. In contrast, those not on any medication experienced a much quicker digestive process, with the same amount of food taking only about four minutes to exit the stomach.

What I am going to do next is synthesize the content of 12 articles¹ written on Ozempic and turn them into 21 questions and answers so by the end you will know more about the subject than the typical doctor handing out prescriptions.

What stood out for me in reading up on the subject was:

Price of Medication: Drugs such as Ozempic and Wegovy, which have gained significant popularity for weight loss, come with a high price tag, often exceeding $1,000 monthly. This substantial cost is a significant consideration for those thinking about using these medications for weight management.

Long-term Commitment: To maintain the benefits, these weight loss drugs require a lifelong commitment. Discontinuing the medication typically results in the loss of its effects, making it necessary for users to continue the treatment indefinitely to sustain the desired outcomes.

Rebound Weight Gain: Clinical studies and patient experiences have shown that once the use of these medications, like Ozempic and Wegovy, is stopped, there is a tendency for the lost weight to be regained. This rebound effect highlights the importance of continuous usage for long-term weight management success.

You can see why the Cartel loves this intervention.

A lifetime commitment at $1,000 pm starting young. Unlike a statin that is a lifetime commitment starting in the 50s and 60s.

They would do anything, literally, to create and maintain this market.

21 Questions and Answers

Here are 21 questions and answers, based on the 12 articles mentioned above, that will leave you much wiser to what is going on in this space. Certainly, much wiser than the typical prescription happy doctor.

1. What is obesity and how is it typically measured in a clinical setting? Obesity is a medical condition characterized by an excess accumulation of body fat, posing significant risks to health. It's typically measured using the Body Mass Index (BMI), a ratio of weight to height. A BMI of 30 or above is classified as obese. This measurement, however, has limitations as it does not distinguish between muscle and fat mass, leading to potential misclassification in individuals like athletes.

2. What are GLP-1 receptor agonists and how do they function in the body? GLP-1 receptor agonists are a class of drugs initially used to treat Type 2 diabetes. They mimic the hormone GLP-1, produced in the intestines, which slows down digestion, increases satiety, decreases glucagon secretion, and stimulates insulin release. This action helps regulate blood sugar levels and, as a side effect, can lead to weight loss.

3. What is Ozempic, and for what conditions is it originally approved? Ozempic, with the active ingredient semaglutide, is a GLP-1 receptor agonist initially approved for managing blood glucose levels in adults with Type 2 diabetes. It's administered as a once-weekly injection and acts by enhancing insulin secretion and reducing appetite, leading to better glycemic control and weight loss as a side effect.

4. How has Ozempic been connected to weight loss? Ozempic’s connection to weight loss stems from its appetite-suppressing properties. While primarily a diabetes medication, its ability to slow gastric emptying and increase satiety inadvertently aids in weight loss. This side effect has led to its off-label use and the development of a higher dose version, Wegovy, specifically for weight management.

5. What is Wegovy and how is it related to Ozempic? Wegovy, also containing semaglutide, is essentially a higher dose version of Ozempic, specifically approved for weight loss. While Ozempic is indicated for diabetes management, Wegovy's higher dosage makes it more effective for significant weight reduction in adults with obesity or overweight with weight-related conditions.

6. What are the common side effects associated with GLP-1 receptor agonists like Ozempic and Wegovy? Common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. More severe side effects can encompass pancreatitis, gallbladder problems, kidney issues, and potentially an increased risk of certain types of cancers. The long-term impact on adolescents and the general population is still being studied, raising concerns about widespread use.

7. How is Ozempic linked to potential side effects like gastrointestinal issues and kidney problems? Ozempic and similar GLP-1 receptor agonists can slow gastric emptying, leading to gastrointestinal issues like gastroparesis, where the stomach takes longer to empty its contents. This can cause symptoms like bloating, nausea, and abdominal discomfort. Additionally, there have been reports of acute kidney injury in patients with pre-existing chronic kidney disease, likely due to changes in fluid and electrolyte balance from gastrointestinal side effects.

8. What are the known connections between Ozempic, Wegovy, and suicidal ideation? There have been reports and investigations into the potential link between GLP-1 receptor agonists and mental health issues, including suicidal ideation. While clinical trials for Wegovy did not support an increased risk, post-market surveillance and anecdotal reports have raised concerns. The European Medicines Agency has initiated reviews into this matter, signaling the need for further investigation.

9. How does the cost of drugs like Ozempic and Wegovy influence patient access and treatment decisions? The high cost of these drugs – over $1,000 per month – significantly impacts patient access, especially for those without insurance coverage. This financial barrier may limit the drugs to a wealthier demographic. Furthermore, the high cost pressures healthcare systems and raises questions about the sustainability of such treatments for obesity.

10. How do pharmaceutical companies directly interact with and influence both doctors and patients regarding the use of weight loss drugs? Pharmaceutical companies exert influence through marketing campaigns and financial incentives. Doctors may receive payments for consulting work or promotional talks, potentially biasing their prescription practices. Direct-to-consumer advertising also influences patient perceptions and demands for these drugs, often emphasizing benefits while downplaying risks.

11. How have these weight loss drugs been marketed, and what ethical concerns does this raise? Marketing strategies for weight loss drugs often play on societal pressures and body image issues, promoting the drugs as quick fixes for weight loss. This can overshadow the importance of lifestyle changes and may lead to over-prescription. Ethical concerns arise from exploiting insecurities for profit and the potential for creating new health issues or exacerbating existing mental health conditions.

12. What are the implications of financial incentives provided by drug companies to doctors for prescribing these medications? Financial incentives from drug companies to doctors can lead to conflicts of interest, where the benefits of the drug might be overstated, and risks downplayed. This could result in increased prescriptions without fully considering patient-specific needs or potential alternative treatments, raising ethical concerns about the objectivity of medical advice.

13. How do societal perceptions of obesity and weight loss influence the demand for drugs like Ozempic? Societal perceptions that stigmatize obesity and idealize thinness drive the demand for quick weight loss solutions. The marketing of drugs like Ozempic exploits these societal pressures, potentially leading to their overuse or misuse. This focus on pharmaceutical solutions may also divert attention from addressing underlying causes of obesity, such as lifestyle and socioeconomic factors.

14. What impact do weight loss drugs have on diabetes management, and how effective are they compared to lifestyle changes? While drugs like Ozempic were initially intended for diabetes management, their role in weight loss can indirectly benefit diabetes control by reducing body weight, a key factor in managing the disease. However, lifestyle changes, such as diet and exercise, are more effective in the long term without the associated costs and side effects of medication.

15. Considering the focus on obesity as a growth sector for pharmaceuticals, what future trends are expected in obesity treatment? The pharmaceutical industry’s focus on obesity is expected to lead to the development of more drugs targeting weight loss, with increased marketing and promotion. This may shift the treatment paradigm from lifestyle-based interventions to medication-based strategies, potentially overshadowing the importance of addressing the root causes of obesity.

16. In the context of the medical field, how does the influence of processed food industries affect the prevalence of obesity and the treatment approaches? The processed food industry, through marketing and lobbying, has influenced dietary guidelines and public perception, often downplaying the role of diet in obesity. This can lead to a misplaced focus on pharmaceutical interventions instead of addressing dietary habits and food choices. The industry’s influence has contributed to the normalization of unhealthy eating patterns, exacerbating the obesity epidemic.

17. What are the potential side effects of rapid weight loss due to GLP-1 medications like Ozempic and Wegovy? GLP-1 medications such as Ozempic and Wegovy, which are used for rapid weight loss, can lead to significant decreases in muscle mass and bone density, as well as a lower resting metabolic rate. This rapid weight loss can result in sarcopenia, a condition typically associated with aging that involves the gradual loss of muscle mass, strength, and function. Sarcopenia can significantly impact quality of life by reducing stamina and the ability to perform daily activities. While these medications are effective in weight reduction, their impact on muscle and bone health is a considerable side effect that needs to be managed.

18. What does the data say about the relationship between GLP-1 drugs and sarcopenia? Data concerning GLP-1 drugs and sarcopenia shows a worrying trend where rapid weight loss induced by these medications leads to a significant loss of lean muscle mass. For instance, in a subset of participants undergoing DEXA scans, which measure bone mineral density, it was found that a substantial portion of the total mass lost was lean muscle mass (about 38%). This is on the higher end of what is typically expected with weight loss, where muscle loss usually constitutes about one-quarter to one-third of total weight loss. The rapidity of weight loss with GLP-1 drugs necessitates extra vigilance in nutritional intake, especially protein, to prevent the onset of sarcopenic obesity, which can negate some of the cardiovascular benefits of weight loss.

19. What is the rationale behind pharmaceutical companies testing weight-loss drugs like Ozempic and Wegovy on children as young as 6 years old? Pharmaceutical companies like Novo Nordisk and Eli Lilly are exploring the use of weight-loss drugs for younger children due to the increasing prevalence of childhood obesity. These companies are conducting clinical trials to extend the use of drugs like Ozempic, Wegovy, and Mounjaro to a younger demographic, recognizing the growing market potential due to the rising obesity rates among children. The aim is to offer a pharmacological solution for weight management in children, an age group where lifestyle and dietary changes can be challenging to implement and monitor effectively.

20. What concerns do medical experts have about using weight-loss drugs in young children? Medical experts express concerns about the use of weight-loss drugs in children, particularly regarding the unknown long-term physical and mental health effects. Since children are in a crucial stage of growth and development, there is apprehension about how these drugs might impact their physical health, including development-related aspects like bone growth. Additionally, there are worries about the potential psychological impact and the reinforcement of a ‘quick-fix’ mentality for weight loss, which could overshadow the importance of healthy lifestyle habits.

21. What are the implications of using weight-loss drugs for societal perceptions of obesity and diet culture? The use of weight-loss drugs can significantly impact societal perceptions of obesity and reinforce a ‘toxic diet culture.’ By offering a pharmacological solution to obesity, there’s a risk of perpetuating the idea that weight loss can be achieved through medication alone, without addressing underlying causes like poor diet, lack of exercise, and socio-economic factors. This approach can also contribute to stigma and pressure, especially among children and teenagers, to conform to certain body standards, potentially leading to unhealthy body image and eating disorders.

Further Reading:

Ozempic Semaglutide Deaths. Endotoxin Hits your Macrophages

Thank You for Being Part of Our Community

Your presence here is greatly valued. If you've found the content enriching, please consider supporting it through a paid subscription. While all our resources are freely available, your subscription plays a vital role. It helps in covering some of the operational costs and supports the continuation of this independent research and journalism work.

Discover Our Free Libraries:

Unbekoming Interview Library: Dive into a world of thought-provoking interviews across a spectrum of fascinating topics.

Unbekoming Book Summary Library: Explore concise summaries of groundbreaking books, distilled for efficient understanding.

Hear From Our Subscribers: Check out the [Subscriber Testimonials] to see the impact of this Substack on our readers.

Share Your Story or Nominate Someone to Interview:

I'm always in search of compelling narratives and insightful individuals to feature. Whether it's personal experiences with the vaccination or other medical interventions, or if you know someone whose story and expertise could enlighten our community, I'd love to hear from you. If you have a story to share, insights to offer, or wish to suggest an interviewee who can add significant value to our discussions, please don't hesitate to get in touch at unbekoming@outlook.com. Your contributions and suggestions are invaluable in enriching our understanding and conversation.

Resources for the Community:

For those affected by COVID vaccine injury, consider the FLCCC Post-Vaccine Treatment as a resource.

Discover 'Baseline Human Health': Watch and share this insightful 21-minute video to understand and appreciate the foundations of health without vaccination.

Books as a Beacon of Knowledge: Recommend 'Official Stories' by Liam Scheff to someone seeking understanding. Start with a “safe” chapter such as Electricity and Shakespeare and they might find their way to vaccination.

Your support, whether through subscriptions, sharing stories, or spreading knowledge, is what keeps this community thriving. Thank you for being an integral part of this journey.

1

1. "The Ever-Expanding Market for Rapid Weight Loss Is a Disaster in the Making" - (Date: 17 Jan 2024, Author: Dr. Joseph Mercola)

2. "Ozempic and Wegovy Gain Popularity for Weight Loss, Also Cause Spike in Emergency Calls for Adverse Side Effects + More" – (Date: 22 Dec 2024, Author: The Defender Staff)

3. "Ozempic Side Effects ‘Well-Known,’ Novo Nordisk Argues + More" – (Date: 7 Nov 2023, Author: The Defender Staff)

4. "The New Weight Loss Drugs: Are they worth the risk?" – (Date: 1 Oct 2023, Author: Dr. Sherri Tenpenny)

5. "Kidney and Gastro Issues Linked to Popular Pill to Get Thin" – (Date: 14 June 2023, Author: Dr. Joseph Mercola)

6. "Popular Skinny Pills Linked to Digestive Problems" – (Date: 25 Oct 2023, Author: Dr. Joseph Mercola)

7. Popular Weight-Loss Drugs Ozempic and Saxenda Under Investigation for Link to Suicidal Thoughts - (Date: 11 July 2023, Author: Brenda Baletti Ph.D.)

8. Ozempic in Teens Is a Mess + More - (Date: 26 May 2023, Author The Defender Staff)

9. Maker of Wegovy, Ozempic Showers Money on U.S. Obesity Doctors + More - (Date: 4 Dec 2023, Author The Defender Staff)

10. Why are the Big Banks Targeting COVID Dissidents? - (Date: 28 July 2023, Author A Midwestern Doctor)

11. "Drug Makers Now Targeting 6-Year-Olds With Popular Weight-Loss Shots" – (Date: 25 Oct 2023, Author: John-Michael Dumais)

12. “Ozempic Can Cause Major Loss of Muscle Mass and Reduce Bone Density” - (Date: 2 May 2023, Author: Cathy Cassata)